Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Morgan

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Seminars in Oncology|June 13, 2003
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584Anne L Thomas, Bruno Morgan, Joachim Drevs, et al.
Trials|April 16, 2015
Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trialGlen Rb Irving, Chinenye Oo Iwuji, Bruno Morgan, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|May 8, 2013
Unsaturated fatty acids differ between hepatic colorectal metastases and liver tissue without tumour in humans: results from a randomised controlled trial of intravenous eicosapentaenoic and docosahexaenoic acidsJames A Stephenson, Omer Al-Taan, Ali Arshad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancerAnne L Thomas, Bruno Morgan, Mark A Horsfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2007
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapyRicky A Sharma, Guy A Van Hazel, Bruno Morgan, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2005
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumoursKlaus Mross, Joachim Drevs, Marianne Müller, et al.
Lancet (London, England)|September 21, 2014
Perimortem trauma in King Richard III: a skeletal analysisJo Appleby, Guy N Rutty, Sarah V Hainsworth, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2010
A phase 2 study of vatalanib in metastatic melanoma patientsNatalie Cook, Bristi Basu, Swethajit Biswas, et al.
Cancer Chemotherapy and Pharmacology|September 21, 2005
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastasesLucy Lee, Sunil Sharma, Bruno Morgan, et al.
Medicine and Science in Sports and Exercise|November 12, 2014
Associations of Sedentary Time with Fat Distribution in a High-Risk PopulationJoseph Henson, Charlotte L Edwardson, Bruno Morgan, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Seminars in Oncology|June 13, 2003
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584Anne L Thomas, Bruno Morgan, Joachim Drevs, et al.
Trials|April 16, 2015
Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trialGlen Rb Irving, Chinenye Oo Iwuji, Bruno Morgan, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|May 8, 2013
Unsaturated fatty acids differ between hepatic colorectal metastases and liver tissue without tumour in humans: results from a randomised controlled trial of intravenous eicosapentaenoic and docosahexaenoic acidsJames A Stephenson, Omer Al-Taan, Ali Arshad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancerAnne L Thomas, Bruno Morgan, Mark A Horsfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2007
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapyRicky A Sharma, Guy A Van Hazel, Bruno Morgan, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2005
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumoursKlaus Mross, Joachim Drevs, Marianne Müller, et al.
Lancet (London, England)|September 21, 2014
Perimortem trauma in King Richard III: a skeletal analysisJo Appleby, Guy N Rutty, Sarah V Hainsworth, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2010
A phase 2 study of vatalanib in metastatic melanoma patientsNatalie Cook, Bristi Basu, Swethajit Biswas, et al.
Cancer Chemotherapy and Pharmacology|September 21, 2005
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastasesLucy Lee, Sunil Sharma, Bruno Morgan, et al.
Medicine and Science in Sports and Exercise|November 12, 2014
Associations of Sedentary Time with Fat Distribution in a High-Risk PopulationJoseph Henson, Charlotte L Edwardson, Bruno Morgan, et al.
Pageof 7